Ultra-Precision Neurology

Molecular Precision Neuro-Stratification

PathoBrainSeq extracts blood cells and uses Whole Genome Sequencing (WGS) and single-cell RNA sequencing (scRNA-seq) to achieve ultra-precision analysis of brain health markers — identifying what other platforms cannot.

🔬 PILOT DATASET — ONGOING RESEARCH

3

Non-AD Controls

4

Early AD Samples

4

Late AD Samples

~79K

Single Cells Analyzed

AD Alzheimer's DEMENTIA Dementia PD Parkinson's HD Huntington's ALS ALS PRION Prion Disease

⚗️ Our Technology

Blood Cell → Brain Health Analysis Pipeline

From a simple blood draw, we extract immune cells and apply WGS and scRNA-seq to analyze molecular patterns that may be associated with neurodegeneration.

🩸

Blood Draw

Blood sample

›

🧫

Cell Isolation

PBMCs / immune cells

›

🧬

WGS

Whole Genome Sequencing

›

🔬

scRNA-seq

Single-cell transcriptomics

›

💻

AI Analysis

Bioinformatics pipeline

›

📋

Analysis Report

Personalized insights

🧬

WGS: Mutation Detection

Identifies disease-causing genetic variants (APOE ε4, LRRK2, HTT CAG repeats) with whole-genome resolution

🔬

scRNA-seq: Disease Progression

Tracks transcriptomic changes at single-cell resolution — monitoring wellness markers before clinical symptoms emerge

💊

Precision Drug Management

Personalised drug response profiling to support informed conversations with your healthcare provider about treatment options

🔬 How It Works

Personal, Proactive, and Precise

Our platform integrates multi-omics data with digital biomarker testing to deliver the most comprehensive neurological health picture available.

1

Blood-Based Genomics

WGS identifies disease-risk mutations. scRNA-seq tracks real-time transcriptomic changes in individual immune cells — providing unprecedented molecular resolution.

2

Digital Cognitive Assessment

The mNeuroMap app provides online-based self-check to quickly check brain health patterns — serving as a preliminary step before NeuroMapDx™ precision genomic analysis.

3

Integrated Analysis Report

Genomic + transcriptomic + digital biomarker data are integrated into a unified report — enabling precise, personalized clinical decisions.

$296B

mHealth Market by 2030

19%

CAGR — Digital Neurology

11

Pilot Dataset (ongoing)

3 control, 4 early AD, 4 late AD

6

Brain Diseases Targeted

✨ Why PathoBrainSeq

What Makes Us Different

The first platform to combine WGS + scRNA-seq + digital biomarkers for multi-disease neurological profiling.

🧬

WGS Mutation Profiling

Whole genome sequencing detects rare and common disease-causing variants across all 6 billion base pairs — providing unmatched genetic resolution for neurological risk.

🔬

scRNA-seq Disease Monitoring

Single-cell RNA sequencing monitors transcriptomic changes at the individual cell level — tracking molecular patterns associated with disease progression over time.

📱

mNeuroMap Digital Platform

Online-based self-assessment platform for quickly checking multiple brain health categories — a preliminary awareness tool for NeuroMapDx precision analysis.

💊

Precision Drug Management

Pharmacogenomic profiling guides drug prescription decisions — identifying which individuals will respond to specific treatments and monitoring efficacy over time.

💡

Drug Development Support

Our multi-omics biomarker data helps pharmaceutical companies identify responders earlier — addressing the chronic failure rate in neurological drug development.

🔒

Data Privacy

We are committed to protecting your data as we build our platform. Security and privacy are core to our architecture from day one.

💬 Anticipated Impact

Why the World Needs PathoBrainSeq

We are in pre-launch phase. These are the transformative impacts we anticipate — and that scientists, clinicians, and advocates are eagerly awaiting.

"A platform that combines WGS and scRNA-seq data with longitudinal digital biomarkers could finally give us the molecular precision we need to match individuals to therapies — something that has eluded neurology for decades."

🧠

Neurological Drug Development

Anticipated impact on clinical trials

"We have seen too many Alzheimer's drugs fail in Phase III because we selected the wrong participants. A multi-omics approach identifying responders at the molecular level before treatment could transform the success rate of neuro drug development."

💊

Pharmaceutical Research

Anticipated impact on drug failure rates

"For families watching a loved one decline, early molecular detection and precise prescription management could mean the difference between years of quality life and accelerated decline. This is the innovation our community needs."

👨‍👩‍👧

Individual & Caregiver Community

Anticipated individual benefit

📱 Digital Wellness Platform

mNeuroMap App

Online-based brain health wellness tool — quickly explore cognitive wellness patterns before in-depth NeuroMapDx genomic analysis.

🚀 Launch mNeuroMap App

This is not a medical device. Results are for personal wellness awareness only and do not constitute a clinical assessment.

📱 Mobile + Web

Multi-Disease Wellness Check Platform

Select your disease focus, complete a battery of research-informed digital exercises, and track results longitudinally. Designed for individuals, caregivers, and healthcare providers.

👤

User Mode

Personal dashboard, monthly score tracking, 30-day rolling averages, profile photo, and PathoBrainSeq genetic data integration.

👨‍👩‍👧

Caregiver Mode

Monitor your linked user's results in real-time. Receive alerts when scores drop below threshold. View longitudinal trends and share PDF reports.

👨‍⚕️

Provider Mode

User list management, detailed longitudinal dashboards, APOE status integration, PDF export, and clinical alert notifications.

Alzheimer's Disease — AD ● Live

Comprehensive AD Wellness Check

Episodic memory, visuospatial navigation, language, executive function, and digital motor biomarkers — combined with APOE genetic status for the most complete early-awareness battery available.

🧠

Cognitive (Research-informed)

Episodic memory · Working memory · Orientation · Language

🎨

Visuospatial / Executive

Pattern recognition · Spatial reasoning · Serial subtraction

📲

Digital Biomarkers

Finger tapping speed · Stroop interference · Word recall

🧬 Genetics

APOE ε4 Status Integration

WGS-derived APOE genotype displayed alongside cognitive scores for integrated wellness overview

📊 Tool

Research-Aligned Battery

Orientation, memory, attention, language, and visuospatial — aligned to published clinical research domains

🏃 Motor

Finger Tapping Speed

10-second digital tapping test measuring bradykinesia — a key early AD neuromotor biomarker

Dementia — General ● Live

Broad Dementia Cognitive Awareness Check

A comprehensive wellness check battery covering all major dementia subtypes — including vascular, Lewy body, and frontotemporal. Includes clinically-informed questions and multi-gene wellness scoring.

🗓️

Orientation & Memory

Temporal orientation · Delayed recall · Attention

🗣️

Language & Executive

Verbal fluency · Serial subtraction · Naming

📋

Functional Assessment

ADL questionnaire · Behavioural change screen

📊 Tool

Cognitive Wellness Check

Clinically-informed cognitive wellness assessment

🔬 Genomics

Multi-gene Risk Panel

WGS-based polygenic risk scoring across APOE, CLU, BIN1, and CR1 loci

Parkinson's Disease — PD ● In Development

Motor & Cognitive PD Battery

Integrates PBWA™ cognitive wellness tracking with finger tapping, spiral drawing, and LRRK2/GBA genetic variant detection for the most comprehensive PD biomarker profile.

🤲

Motor Assessment

Finger tapping · Spiral drawing · Gait analysis

😴

Non-Motor Symptoms

Sleep quality · Smell assessment · Autonomic screen

🧬 Genetics

LRRK2 / GBA / SNCA Panel

WGS-derived PD-specific variant analysis — in development

Huntington's Disease — HD ● In Development

HD Comprehensive Self-Check

Processing speed, oculomotor function, and HTT CAG repeat analysis. Behavioural change self-check for early HD awareness and progression monitoring.

⚡

Processing Speed

Stroop test · Reaction time · Serial 7s

🧬 Genetics

HTT CAG Repeat Analysis

Definitive HD genetic test via WGS — in development

ALS (Lou Gehrig's) ● In Development

ALS Digital Biomarker Screen

Motor neuron decline tracking, speech pattern analysis, limb strength assessment, and SOD1/C9orf72 genetic panel for comprehensive ALS biomarker profiling.

💪

Motor Neuron Function

Grip strength proxy · Speech analysis · Breathing screen

🧬 Genetics

SOD1 / C9orf72 Panel

ALS-associated genetic variants via WGS — in development

Prion Disease ● In Development

Prion Disease Progression Tracking

Rapid functional decline monitoring, cerebellar function, myoclonus monitoring, and prion-specific biomarker tracking for early detection of prion disease progression.

📉

Rapid Decline Monitoring

Velocity scoring · Cerebellar function · Myoclonus

🧬 Genetics

PRNP Gene Analysis

Prion protein gene variant detection — in development

📋 Service Status

What's Available Now

PathoBrainSeq is in active research and pre-commercial phase. We are transparent about what is live, what is in development, and what's on our roadmap.

● LIVE NOW

Alzheimer's Disease & Dementia — Active Services

Our current pilot dataset includes 3 non-AD controls, 4 early AD, and 4 late AD samples (11 total, ~79,000 single cells analyzed). We are actively accepting research collaborations, pilot study partnerships, and early clinical inquiries for AD and Dementia awareness.

✅ Available

WGS-based AD Genetic Panel

APOE ε4, APP, PSEN1/2 variant analysis from blood

✅ Available

scRNA-seq Progression Monitoring

Disease progression tracking at single-cell resolution

✅ Available

mNeuroMap Digital Assessment

Web-based cognitive & motor biomarker testing

⚙️ IN DEVELOPMENT

Parkinson's & Huntington's

Motor biomarker validation, LRRK2/GBA/HTT genetic panel development, and scRNA-seq signature identification ongoing.

⚙️ Motor biomarker protocols in validation
⚙️ Genetic panel design complete — testing phase
⚙️ ETA: Research partnerships open now

🗺️ ROADMAP

ALS & Prion Disease

Planned for Phase 2 expansion following core AD/PD/HD platform validation and series A funding.

🗺️ SOD1/C9orf72 panel (ALS) — planned
🗺️ PRNP analysis (Prion) — planned
🗺️ Global market expansion planned

🧬 Request NeuroMapDx Services

Whether you're a clinician, researcher, or institution — contact us to discuss NeuroMapDx blood-based genomic testing, research partnerships, or pilot study participation.

🧬 NeuroMapDx

NeuroMapDx — Blood-Based Early Precision Analysis

Early precision analysis of neurodegenerative disease markers through blood-based WGS & scRNA-seq genomic analysis — detecting disease-related mutations and monitoring progression before symptoms appear.

🧬 NeuroMapDx · WGS

Whole Genome Sequencing

WGS provides comprehensive coverage of the entire genome — detecting disease-causing mutations, structural variants, and pharmacogenomic markers that targeted panels miss.

🧬

AD Mutation Panel (WGS)

APOE ε4 genotyping, APP, PSEN1, PSEN2 rare variant detection, and polygenic risk scoring across 75+ AD-associated loci. Identifies both monogenic and complex genetic risk.

🔗

PD/HD Genetic Panels (WGS)

LRRK2, SNCA, GBA, PINK1 for Parkinson's. HTT CAG repeat expansion analysis for Huntington's — the definitive genetic test. In development phase.

💊

Pharmacogenomics (WGS)

Identifies which patients will respond to specific AD/PD drugs — guiding prescription decisions and helping pharmaceutical companies select responders for clinical trials.

🔬 NeuroMapDx · scRNA-seq

Single-Cell RNA Sequencing

scRNA-seq goes beyond genetics — measuring which genes are actually active in each individual cell at the time of sampling, revealing disease progression dynamics invisible to WGS.

📈

Disease Progression Monitoring

Sequential scRNA-seq samples reveal transcriptomic changes over time — tracking neuroinflammatory signatures, microglial activation, and synaptic gene expression changes as disease progresses.

🎯

Cell-Type-Specific Signatures

Identifies which specific immune cell populations are dysregulated in each patient — providing cell-resolution insights that bulk RNA-seq cannot deliver.

🔁

Treatment Response Tracking

Pre- and post-treatment scRNA-seq reveals molecular response to therapy at single-cell resolution — enabling precision monitoring of drug efficacy and early detection of non-response.

📬 Request NeuroMapDx Services

Ready to discuss blood-based WGS, scRNA-seq, or integrated multi-omics early precision diagnostics? Leave your contact below and our team will reach out within 24 hours.

👥 Our Team

About PathoBrainSeq

A team of seasoned neuroscientists, bioinformaticians, and clinicians united by a mission to revolutionize brain health analysis.

🎯 Our Mission

Precision Insights for Personalized Wellness

We believe that ultra-precision neurological analytics — combining WGS, scRNA-seq, and digital biomarkers — should be accessible to individuals and clinicians everywhere.

Brain diseases like Alzheimer's have seen decades of drug development failures — primarily because we haven't had the molecular tools to select the right patients. PathoBrainSeq is building those tools.

The Gap We Fill

❌

Single-disease platforms — existing tools address only one condition at a time

❌

No transcriptomics — genetic panels miss dynamic disease progression signals

❌

Digital-genomics gap — cognitive apps and genetic tests are siloed, not integrated

✅

PathoBrainSeq solves all three — WGS + scRNA-seq + digital biomarkers, integrated

👥 Leadership Team

Experienced. Multidisciplinary. Driven.

Neuroscience Expert

20 Years of Brain Disease Research

Two decades dedicated to neurodegenerative disease research — spanning molecular mechanisms, translational biomarker development, and clinical trial design for Alzheimer's and related dementias. Founded PathoBrainSeq to bridge the gap between genomic discovery and clinical diagnostics.

Bioinformatics Expert

Computer Science + 15 Years Bioinformatics

Computer Science foundation with 15 years of applied bioinformatics experience — building large-scale genomics pipelines, WGS analysis workflows, and scRNA-seq processing platforms. Architect of PathoBrainSeq's multi-omics analytical infrastructure.

Academic Neuroscientist

Professor & 15-Year Brain Disease Researcher

Full professor at a leading research institution, with 15 years of focused brain disease research and an extensive publication record in neurodegeneration. Brings rigorous academic standards and cutting-edge scientific expertise to PathoBrainSeq's research agenda.

US & Korean Medical Board Physicians

Clinical Advisors — US & South Korea

Our Clinical Advisory Board comprises board-certified physicians from both the United States and South Korea — actively caring for neurological patients in clinical practice. They provide real-world clinical validation, patient insights, and regulatory guidance for both US FDA and Korean MFDS pathways.

📬 Get In Touch

Contact PathoBrainSeq

Whether you're a patient, clinician, researcher, pharma partner, or investor — we want to hear from you.

Let's Connect

We're building the future of neuro-health technology — and we need collaborators, patients, clinicians, and partners. Every conversation matters.

🌐

Website

www.pathobrainseq.com

🇺🇸

USA

United States — Research & Clinical Partnerships

🇰🇷

Korea

South Korea — Clinical Advisory & Regulatory

🏥

For Clinicians

B2B clinical integration, pilot programs, EHR API

🔬

For Researchers

Multi-omics data collaboration, biomarker validation

💼

For Investors

Seed/Series A — Contact for pitch deck & investor materials →

Send Us a Message

First Name

Last Name

Email

I am a...

Subject

Message

✅

Message Sent!

Thank you for reaching out. Our team will respond within 1-2 business days.